Arbutus Biopharma Corp (ABUS) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection. The company's primary pipeline assets include imdusiran (AB-729), an RNAi therapeutic in Phase 2a trials, and AB-101, an oral PD-L1 inhibitor in Phase 1a/1b trials. This report covers the quarterly period ended June 30, 2024.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6 Months 2024 | 6 Months 2023 |
|---|---|---|---|---|
| Total Revenue | $1,726 | $4,651 | $3,258 | $11,338 |
| Net Loss | $(19,796) | $(17,094) | $(37,671) | $(33,433) |
| Loss Per Share (Basic/Diluted) | $(0.11) | $(0.10) | $(0.21) | $(0.20) |
| Operating Expenses | $23,309 | $23,036 | $44,204 | $47,136 |
| Cash & Cash Equivalents (End of Period) | $62,788 | $27,197 | $62,788 | $27,197 |
| Total Liquidity (Cash + Investments) | $148,513 | $132,287 | $148,513 | $132,287 |
| Debt | $0 | $0 | $0 | $0 |
Note: Revenue includes non-cash royalty revenue related to the sale of future royalties on ONPATTRO. The company has no outstanding debt.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 63% in Q2 2024 compared to Q2 2023. This was driven by a significant decrease in license revenue from the Qilu Pharmaceutical agreement (down from $3.0M to $0.5M) and lower royalty revenue from ONPATTRO sales.
- Expense Management: Research and development (R&D) expenses decreased by $2.1 million in Q2 2024 compared to the prior year, primarily due to the discontinuation of the coronavirus and AB-161 programs in late 2023. General and administrative (G&A) expenses increased by $1.6 million, largely due to higher litigation costs.
- Liquidity Improvement: Cash and cash equivalents increased from $26.3 million at year-end 2023 to $62.8 million at June 30, 2024. This increase was fueled by $44.1 million in net proceeds from the sale of common shares under the Open Market Sale Agreement (ATM) during the first six months of 2024.
- Interest Income: Interest income rose to $1.8 million in Q2 2024 from $1.5 million in Q2 2023, reflecting higher market interest rates on the company's investment portfolio.
Guidance, Outlook, and Material Events
- Restructuring and Cost Reduction: Effective August 1, 2024, the Board approved a 40% workforce reduction to streamline operations. The company ceased all discovery efforts and discontinued the IM-PROVE III clinical trial. A one-time restructuring charge of approximately $3.0 million to $4.0 million is expected in Q3 2024, including $2.9 million in cash severance.
- Cash Runway: Management expects current cash resources ($148.5 million) to fund operations into the fourth quarter of 2026. The company anticipates a net cash burn between $63 million and $67 million for the full year 2024.
- Clinical Progress:
- Imdusiran: Data from the IM-PROVE I trial showed that 33% of patients in one cohort achieved undetectable HBsAg at end-of-treatment, sustained 24 weeks post-treatment. IM-PROVE II data showed statistical significance in HBsAg reduction when combined with VTP-300.
- AB-101: The Phase 1a/1b trial is ongoing. Preliminary data from Part 1 showed the drug was well-tolerated with dose-dependent receptor occupancy. Part 2 data is expected in the second half of 2024.
- Litigation:
- Moderna: The trial date for the patent infringement lawsuit was moved from April 2025 to September 24, 2025, following a stipulation to extend discovery. The court previously ruled in Arbutus's favor on claim construction.
- Pfizer/BioNTech: Litigation is ongoing; a claim construction hearing date has not been set.
- Acuitas: The declaratory judgment lawsuit filed by Acuitas was dismissed by the court in May 2024.
Investor Verification Checklist
- Restructuring Impact: Verify the exact timing and cash outflow of the $3.0M-$4.0M restructuring charge in Q3 2024 and its effect on the projected 2024 cash burn.
- Revenue Sustainability: Assess the long-term impact of the Qilu license revenue decline and the dependency on ONPATTRO royalty sales for near-term cash flow.
- ATM Capacity: Confirm the remaining capacity under the Open Market Sale Agreement (approximately $25.4 million as of June 30, 2024) and the company's reliance on equity raises to extend the runway.
- Litigation Outcomes: Monitor the September 2025 trial date for the Moderna lawsuit and the status of the Pfizer/BioNTech case, as these represent potential significant non-operating income sources.
- Clinical Data Readouts: Track the release of preliminary data for the AB-101 Phase 1 trial and the additional cohort of the IM-PROVE II trial expected in the second half of 2024.